linjc16/ctgov huggingface dataset:
Growth Hormone's Effect on the Cardiovascular System

Study Overview
=================
Brief Summary
-----------------
To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-matched healthy population.

Detailed Description
-----------------
Growth hormone deficiency (GHD) is associated with increased cardiovascular morbidity and mortality. The effects of such a deficiency include decreased exercise capacity and tolerance, impaired cardiac function, a central fat redistribution, increased peripheral arterial resistance, and an unfavorable lipid profile. These effects have been found to be reversed with appropriate replacement therapy with recombinant human growth hormone. We plan to utilize several experimental systems to further investigate the role of growth hormone (GH) in maintaining cardiovascular health. In particular, we would like to further understand the interaction of GH with Plasminogen-activator-inhibitor-1 (a major activator of the fibrinolytic system) as well as the role of GH in the maintenance of vascular function.

Official Title
-----------------
The Role of Growth Hormone in Cardiovascular Health

Conditions
-----------------
Growth Hormone Deficiency

Intervention / Treatment
-----------------
* Drug: Growth Hormone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult between the ages of 18 and 65 Documented Growth Hormone Deficiency as defined by a peak Growth Hormone during a GHRH-Arginine Stimulation test not exceeding 9.5 ng/ml Exclusion Criteria: Personal history of cardiovascular disease (previous myocardial infarction or known coronary artery disease) or diagnosis of heart disease between study visits. Personal history of diabetes mellitus or development of diabetes between study visits. Initiation of an anti-cholesterol medication or anti-hypertensive between baseline and follow-up study visit. Initiation of regular tobacco use between baseline and follow-up study visit. Pregnancy or nursing Current daily use of any drug known to affect the fibrinolytic system: Aspirin, Aggrenox, Plavix, Persantine, Ticlid, Pletal, Trental, Lovenox, Coumadin, Agrylin, and Hydroxyurea.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Growth Hormone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Growth Hormone, Cardiovascular System
Efficacy of Median Nerve Block Performed Using Echographic Guidance

Study Overview
=================
Brief Summary
-----------------
Observational study of the efficacy of median nerve blocks performed using echographic guidance in patients presenting with or without carpal tunnel syndrome.

Official Title
-----------------
Efficacy of Median Nerve Block Performed Using Echographic Guidance

Conditions
-----------------
Orthopedic

Intervention / Treatment
-----------------
* Procedure: median nerve block
* Procedure: median nerve block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: short surgical procedure (less than 30 minutes) on the hand, regional anesthesia at the elbow involving the median nerve. Exclusion Criteria: age less than 18 years, pregnant woman mental incapacity, poor understanding of French.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients with a carpal tunnel syndrome | Procedure: median nerve block<br>* median nerve block performed under echographic guidance<br>|
| 2<br>patients without a carpal tunnel syndrome | Procedure: median nerve block<br>* median nerve block performed under echographic guidance<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| light touch sensibility |  | 30 minutes following block performance | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ice touch sensibility |  | 30 minutes following block performance | 
| motor block |  | 30 minutes following block performance | 
| paresthesia |  | during nerve block procedure | 
| vascular puncture |  | during nerve block procedure |
Combination Chemotherapy in Treating Older Patients With Solid Tumour,

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating older patients with solid tumour.

Detailed Description
-----------------
OBJECTIVES: Primary To determine a prognostic scale of the feasibility of chemotherapy (at least two-thirds of the dose intensity usually administered) in patients aged 75 years or older with solid tumour. Secondary To evaluate the efficacy, in terms of clinical and/or biological response, of treatments administered. To evaluate the incidence of severe (grade 3-4) toxicity. OUTLINE: This is a multicenter study. Patients receive one of the following regimens according to cancer diagnosis and principal investigator preference. All regimens last 3 months.

Official Title
-----------------
Study of a Scale Predicting the Feasibility of Chemotherapy in Patients Aged 75 Years or Older With Solid Tumour

Conditions
-----------------
Solid Tumor Regardless of Localization and Stage

Intervention / Treatment
-----------------
* Other: chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically confirmed solid tumour regardless of localization or stage PATIENT CHARACTERISTICS: > or = 75 years patient planned to receive > or = 2/3 of standard dose of the first cycle PRIOR CONCURRENT THERAPY: Chemonaive patient.

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Chemotherapy<br>chemotherapy regimen | Other: chemotherapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| chemotherapy feasibility | ability to deliver at least 3 months of the planned regimen therapy. | from inclusion to 3 months | 
| Number of patients receiving therapeutic dose-intensive therapy (doses must be at least equivalent to two-thirds the dose that is usually administered according to AMM recommendations) | dose reduction < 33% | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Grade 3-4 toxicities according to NCI-CTCAE version 3 |  | from inclusion to 3 months |
Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if there is a correlation between tumor response after 3 doses of chemotherapy by induction using Docetaxel, Cisplatine and 5-Fluorouracile for advanced stage epidermoid carcinomas of the upper aero digestive tract and the presence of one or a combination of 3 genetic polymorphisms and/or 5 intra-tumoral transcriptional modifications.

Official Title
-----------------
Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers

Conditions
-----------------
Carcinoma, Squamous Cell, Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Hypopharyngeal Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Squamous cell carcinoma originating in the mouth, oropharynx, larynx or hypopharynx has been histologically documented. The disease is at one of the following UICC 2002 stages, regardless of ganglion status: T3 MO or T4 MO Treatment via chemotherapy, radiotherapy or surgery (except for the diagnostic biopsy) has not started The pluridisciplinary committee as ruled out surgical options for technical or functional reasons Absence of distant metastases OMS general health status between 0 and 2 Patient has given informed consent Patient is affiliated with a social security system Exclusion Criteria: Undifferentiated squamous cell carcinomas in the nasopharynx (UCNT) Another cancer priorly treated with one of the following chemotherapies: Docetaxel, Cisplatin, 5-Fluorouracile Creatininemia > 2 mg/dl and/or creatinine clearance < 60ml/min Patient under guardianship Presence of another severe pathology including: severe or chronic cardiac, renal and/or hepatic insufficiencies severe medullary hypoplasia severe autoimmune disease psychosis or senility

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All patients<br>As the trial progresses, patients will be classified as either chemotherapy responders or non-responders. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| %change in tumor volume before and after chemotherapy (baseline versus 62 days) | Tumor volume is calculated according to Labadie et al 2000 | 62 days |
Patient Time and In-hospital Delay of Surgery Association With Complicated Appendicitis

Study Overview
=================
Brief Summary
-----------------
This is a retrospective observational study with its main aim of evaluating possible factors associated with complicated appendicitis. Current literature supports time from symptom onset until registration as the main and maybe only determinant of the outcome if patients are operated on within 24 hours. We wish to evaluate whether this is true in all patients, or there are subgroups in which time from registration to operation is associated with complicated appendicitis.

Detailed Description
-----------------
The data to be analyzed is that of patients operated on acutely for suspected appendicitis within 10 years in one medical center. Patients undergoing interval or incidental appendectomies will not be included. The endpoint to be evaluated is complicated appendicitis (gangrenous, abscess, perforated). The independent variables will include mainly sex, age, patient time (time from symptom onset to registration), hospital time (time from registration to operation), and missed diagnosis.

Official Title
-----------------
In-hospital Delay of Surgery Increases the Rate of Complicated Appendicitis in Patients Presenting With Short Duration of Symptoms: a Retrospective Cohort Study

Conditions
-----------------
Acute Appendicitis

Intervention / Treatment
-----------------
* Other: surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and female patients of all ages who underwent appendectomy of acute appendicitis in a single medical center between December 1, 2006, and December 31, 2016 Exclusion Criteria: interval appendectomy, incidental appendectomy, appendectomy after failed antibiotic treatment for either acute appendicitis or peri-appendicular abscess patients with a non-inflamed appendix those in whom symptom onset before hospitalization was not noted.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proportion of complicated appendicitis | complicated appendicitis defined as either gangrenous appendicitis, perforation with abscess, perforation with local peritonitis, perforation with diffuse peritonitis | finding during surgery/pathology | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Appendicitis, Ruptured Appendicitis, Appendectomy, Timing of Surgery
Neurophysiology and Anatomy of Severe Intraventricular Hemorrhage (IVH)

Study Overview
=================
Brief Summary
-----------------
Currently, when premature infants develop severe intraventricular hemorrhage (IVH), a type of intracerebral bleed, there are no proven therapeutic interventions to prevent the devastating consequences of this event. These children will be likely to develop cerebral palsy or severe cognitive delays. The purpose of our study is to characterize differences in brain physiology, imaging, and function between premature infants with severe IVH and controls. The goals for gathering this information are to generate baseline data, which could facilitate early screening for complications of IVH in premature infants. These baseline data would also allow the design and implementation of early therapeutic interventions to help rehabilitate premature infants with severe IVH.

Official Title
-----------------
Influence of Altered Cerebral Spinal Fluid and Arterial Flows on Cerebral Processing Functions in Premature Infants With Severe Intraventricular Hemorrhage

Conditions
-----------------
Intracranial Hemorrhages, Prematurity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Birth weight < 1500 grams for all inborn infants and age less than 14 post-natal days Birth weight < 1500 grams for all outborn infants transferred to the VCH NICU within the first 72 hours after birth and age less than 14 post-natal days Parents agree to their infant's participation and give informed written consent. Exclusion Criteria: Unable to obtain informed consent. Congenital brain malformations leading to hydrocephalus Genetic and metabolic disorders leading to cerebral pathology

Ages Eligible for Study
-----------------
Maximum Age: 14 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Severe IVH<br>Infants born at less than 1500g with diagnosis of Grade II or IV IVH | |
| control<br>infants born at less than 1500g without IVH on HUS | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neurodevelopmental outcome | BSID III scores | 3 years |
Safety of Remifentanil Infusion

Study Overview
=================
Brief Summary
-----------------
The effect of maintenance remifentanil infusion with target controlled infusion during laryngeal mask airway removal on hemodynamic parameters and emergence quality is going to be investigated.

Detailed Description
-----------------
In all patients (control group and remifentanil group induction of anesthesia will be achieved with desflurane and remifentanil.Anesthesia will be maintained with remifentanil (1-4 ng/mL) by TCI target controlled infusion, and desflurane . Throughout the surgery hemodynamic parameters are going to be recorded. As soon as the surgery has been finished, in control group remifentanil infusion and desflurane inhalation is going to be stopped.In remifentanil group,desflurane inhalation is going to be stopped and remifentanil infusion will be maintained until the removal of LMA. During the emergence period the time of eye opening, hemodynamic parameters and emergence quality (score 1-2)are going to be recorded.

Official Title
-----------------
The Effects of Maintenance a Remifentanil Infusion on the Hemodynamic Variables and Recovery Quality

Conditions
-----------------
Urinary Tract Problem

Intervention / Treatment
-----------------
* Drug: remifentanil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II status aged 18-60 years old presenting for ureterorenoscopy Exclusion Criteria: history of hypertension asthma and chronic obstructive lung disease recent respiratory tract infections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ultiva,remifentanil,opioid,analgesic<br>Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery | Drug: remifentanil<br>* 1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.<br>|
| No Intervention: control<br>Control:Remifentanil stopped at the end of the surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Smooth cLMA Removal Condition (Score 1) | cLMA removal was accepted as successful (score 1) if none of the complications coughing, teeth clenching, gross purposeful movements, breath holding, laryngospasm, and desatura- tion to SpO2\90% was observed. If any of these compli- cations was observed it was regarded as unsuccessful (score 2) | At the end of the surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Remifentanil, Laryngeal mask airway removal, Hemodynamic changing, Infusion, Ureterorenoscopy
Study on Therapy of Non-invasive Prolactinoma

Study Overview
=================
Brief Summary
-----------------
the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.

Detailed Description
-----------------
Non-invasive prolactinomas were treated by transsphenoidal surgery or Dopamine agonist until now. However，this two type therapies were controversial. The study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.

Official Title
-----------------
Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma

Conditions
-----------------
Prolactinoma

Intervention / Treatment
-----------------
* Procedure: transsphenoidal surgery treatment
* Drug: dopamine agonist treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non-invasive prolactionma Exclusion Criteria: invasive prolactioma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: transsphenoidal surgery treatment<br>Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon | Procedure: transsphenoidal surgery treatment<br>* transsphenoidal surgery treatment<br>* Other names: TSS;|
| Experimental: dopamine agonist treatment<br>Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma | Drug: dopamine agonist treatment<br>* Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona<br>* Other names: DA;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endocrine remission rate | After intervention, blood prolactin normalization rate | five-year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-invasive prolactinoma